ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)
Abstract
Background: Dacomitinib (D) is an orally available, irreversible, small-molecule inhibitor of EGFR (HER1), HER2, and HER4. It has shown activity in preclinical studies on EGFR mutant cell lines, including those resistant to gefitinib (G). In a phase II trial of non-small-cell lung cancer (NSCLC) patients (pts) who received 1st-line D, 76% of 45 pts with confirmed EGFR exon 19 or 21 activating mutations (m) experienced a partial response (PR)....
Paper Details
Title
ARCHER 1050: first-line dacomitinib vs gefitinib for advanced NSCLC in patients with EGFR activating mutation(s)
Published Date
Nov 1, 2015
Journal
Volume
26
Pages
vii82 - vii82
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History